Results 261 to 270 of about 318,819 (293)
Some of the next articles are maybe not open access.
Monoclonal antibody-induced cytokine-release syndrome
Expert Review of Clinical Immunology, 2009Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy. Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a few mAbs is cytokine-release syndrome (CRS). These mAbs include: alemtuzumab, muromonab-CD3, rituximab, tosituzumab, CP-870,893, LO-CD2a/BTI-322 and TGN1412. By contrast,
Peter J, Bugelski +4 more
openaire +2 more sources
Towards Remote Continuous Monitoring of Cytokine Release Syndrome
2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC), 2022Cytokine release syndrome (CRS) is a noninfec-tious systemic inflammatory response syndrome condition and a principle severe adverse event common in oncology patients treated with immunotherapies. Accurate monitoring and timely prediction of CRS severity remain a challenge. This study presents an XGBoost-based machine learning algorithm for forecasting
Michael J. Pettinati +4 more
openaire +2 more sources
Management Principles Associated With Cytokine Release Syndrome
Seminars in Oncology Nursing, 2019To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS).A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events.Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research.
Brittney, Baer +2 more
openaire +2 more sources
Cytokine release syndrome: a primer for generalists
Adverse Drug Reaction Bulletin, 2019Summary Cytokine release syndrome (CRS) is an adverse drug reaction that is poorly understood but is likely to be increasingly common as more immunotherapeutics are being developed and licensed, principally in the treatment of cancer.
Tiago Soares, Henry Fok
openaire +1 more source
Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)
Bone Marrow Transplantation, 2020International ...
Wallet, Florent +7 more
openaire +3 more sources
Cytokine-Release Syndrome: Overview and Nursing Implications
Clinical Journal of Oncology Nursing, 2007Cytokine-release syndrome is a symptom complex associated with the use of many monoclonal antibodies. Commonly referred to as an infusion reaction, it results from the release of cytokines from cells targeted by the antibody as well as immune effector cells recruited to the area.
openaire +2 more sources
Cytokine Release Syndrome and Sepsis
Infectious Disease Clinics of North America, 2022Janhavi Athale +2 more
openaire +1 more source
Cytokine release syndrome: Who is at risk and how to treat
Best Practice & Research Clinical Haematology, 2017T-cell engaging therapies such as blinatumomab and anti-CD19 chimeric antigen receptor (CAR) T cells have revolutionized our approach to patients with relapsed and refractory acute lymphoblastic leukemia (ALL). However, the immune activation responsible for high remission rates is also responsible for the unique treatment-related toxicity of cytokine ...
openaire +2 more sources
Understanding cytokine release syndrome
Intensive Care Medicine, 2017Philipp Gödel +2 more
openaire +2 more sources
Medicina Intensiva (English Edition)
In recent years, there has been an increase in the number of patients affected by oncohematologic diseases in developed countries due to the improved survival rates and quality of life. This increase has generated a greater need for care in intensive care units (ICU), mainly due to complications related to immunosuppression, treatment toxicity or ...
Eric, Mayor-Vázquez +7 more
openaire +2 more sources
In recent years, there has been an increase in the number of patients affected by oncohematologic diseases in developed countries due to the improved survival rates and quality of life. This increase has generated a greater need for care in intensive care units (ICU), mainly due to complications related to immunosuppression, treatment toxicity or ...
Eric, Mayor-Vázquez +7 more
openaire +2 more sources